Latest Gene therapy Stories
PHILADELPHIA, June 2, 2014 /PRNewswire/ -- Spark Therapeutics, Inc., a late-stage gene therapy company developing treatments for a wide range of rare, debilitating diseases, announced today that company
Groundbreaking Nature Publication Describes Successful ZFN Driven Genome Editing in Long-Term Repopulating Stem Cells Necessary for Clinical Translation RICHMOND, Calif., May 28, 2014
Gene therapy leader to advance its deep pipeline of rare disease programs including its lead Phase 3 product candidate for RPE65-related blindness PHILADELPHIA, May 27, 2014 /PRNewswire/
For the first time researchers have succeeded in altering HIV virus particles so that they can simultaneously, as it were, 'cut and paste' in our genome via biological processes.
SB-728-T-Treated Subject Maintains Control of Viral Load for 45 Weeks Without Anti-Retroviral Drugs RICHMOND, Calif., May 27, 2014 /PRNewswire/ -- Sangamo BioSciences, Inc.
Transparency Market Research added a new report "Global Gene Therapy Market: Analysis, Size, Share, Growth, Trends and Forecast 2013 - 2019" to its report store.
In Addition, Toca 511 Clinical Data to be Presented at American Society of Clinical Oncology Annual Meeting SAN DIEGO, May 22, 2014 /PRNewswire/ --
RICHMOND, Calif., May 14, 2014 /PRNewswire/ -- Sangamo BioSciences, Inc.
Gene therapy leader will house business operations and manufacturing in a growing and dynamic biotech hub PHILADELPHIA, May 13, 2014 /PRNewswire/ --
MOUNTAIN VIEW, Calif., May 5, 2014 /PRNewswire/ -- Clontech Laboratories, Inc., a wholly-owned subsidiary of Takara Bio Inc., today announced that it has partnered with Vectalys SAS to combine
- A handkerchief.
- In general, any miraculous portrait of Christ.
More Images (1 images) »